Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.

Authors

null

Kathryn E. Weaver

Wake Forest University School of Medicine, Winston-Salem, NC

Kathryn E. Weaver , Emily Van Meter Dressler , Heidi D. Klepin , Simon Craddock Lee , Sydney Smith , Brian J Wells , W. Gregory Hundley , Glenn Jay Lesser , Chandylen L Nightingale , Alyssa Throckmorton , Marcia Hernandez , Jenny Marie Hanna , Ian T. Lackey , Kevin Heard , Randi E Foraker

Organizations

Wake Forest University School of Medicine, Winston-Salem, NC, Department of Population Health, University of Kansas School of Medicine, Kansas City, KS, Virginia Commonwealth University, Richmond, VA, Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, NC, Baptist Cancer Center, Memphis, TN, Mercy Hospital Springfield, Springfield, MO, Mercy Clinic Oncology- Fort Smith, Fort Smith, AR, Washington University School of Medicine Saint Louis, St. Louis, MO, BJC HealthCare, St. Louis, MO, Washington University in St. Louis School of Medicine, St. Louis, MO

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Practice guidelines recommend cardiovascular risk assessment and counseling for cancer survivors. The Automated Heart-Health Assessment study (AH-HA: WF-1804CD, NCT# 03935282) evaluated a novel electronic health record (EHR) clinical decision support tool based on American Heart Association Simple 7 cardiovascular health (CVH) factors to promote provider-patient CVH discussions in outpatient oncology. Methods: This clinic-randomized trial (R01CA226078), coordinated by the Wake Forest NCORP Research Base (UG1CA189824), randomized NCORP oncology practices using the Epic EHR to the AH-HA tool or usual care and enrolled survivors receiving routine care at least 6 months post-curative cancer treatment. The tool rendered an interactive display of risk factors, automatically populated from the EHR, alongside a tab indicating receipt of cancer treatments with cardiotoxic potential. Survivors at AH-HA sites had tool access during a routine visit; survivors at usual care sites did not. Immediately post-visit, each survivor was asked about counseling on 7 CVH factors [body mass index, physical activity, diet, smoking status, blood pressure, cholesterol, and glucose]. The primary endpoint is survivor-reported discussion of non-ideal or missing CVH factors; with 8 randomized practices (ICC=0.03), the study design had 82% power to detect a difference of 20% reported discussions in usual care versus 40% in AH-HA. Additional clinical endpoints were documentation of CVH discussions, referrals to primary care and cardiology, and change in CVH factors over 12 months (ongoing). A mixed effects logistic regression model assessed the effect of AH-HA on CVH discussions between the arms, with study arm as a fixed effect and practice as a random effect. Results: 5 usual care and 4 AH-HA practices enrolled 645 survivors from 10/1/2020- 2/28/2023. The majority had breast cancer (82%; 8% endometrial, 5% colorectal, 5% prostate, lymphoma or multiple types). Most survivors were female (96%; 84% White/non-Hispanic, 8% Black; 3% Hispanic; mean age= 62 yrs and median time since diagnosis=3.6 yrs). 18 participants (3%) did not complete necessary assessments, leaving 627 evaluable. 87% of providers (n=15) rated the tool utility and ease of use positively. Conclusions: The AH-HA tool was acceptable and effective at promoting CVH discussions during routine follow-up care for survivors and referrals to primary care. Clinical trial information: NCT03935282.

Model Estimate (95% CI)AH-HA Tool (n=291, 4 practices)Usual Care (n=336, 5 practices)p-value
Proportion of survivors reporting ≥1 non-ideal or missing CVH factor discussed97.6% (95.6, 98.7)54.8% (44.8, 64.4)<0.001
# non-ideal or missing factors discussed 4.06 (3.46, 4.66)1.26 (0.72, 1.81)<0.001
# of factors documented as discussed in EHR3.83 (1.82, 5.84)0.78 (-1.02, 2.58)0.03
Reported referral to primary care38.6% (33.2, 444)25.0% (16.8, 35.5)0.03

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Health Promotion/Behaviors

Clinical Trial Registration Number

03935282

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA12007)

DOI

10.1200/JCO.2023.41.17_suppl.LBA12007

Abstract #

LBA12007

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

Using clinical pathways to identify patient candidates for survivorship in testicular cancer.

First Author: Matthew Rice

Abstract

2023 ASCO Quality Care Symposium

Loss to primary care provider follow-up among survivors five to seven years post-diagnosis.

First Author: Alexandra G. Peluso

Abstract

2023 ASCO Annual Meeting

Value-driven colorectal cancer survivorship through partnership with primary care.

First Author: Gloria Hui Jia Chan

First Author: Sarah A Birken